查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356860

高雪氏症市場報告：至2030年的趨勢、預測與競爭分析

Gaucher Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

高雪氏症的趨勢和預測

預計到2030年，全球高雪氏症市場將達到20 億美元，2024年至2030年年複合成長率為 2.1%。該市場的主要促進因素是遺傳異常，高雪氏症及其相關症狀的盛行率不斷增加，消費者對診斷的認知不斷提高以及治療選擇的便利可得性。全球高雪氏症市場的未來前景廣闊，醫院、專科診所和居家照護市場充滿機會。

高雪氏症市場洞察

Lucintel 預測，1 型預計在預測期內成長最快，因為它不影響中樞神經系統，而且是一種非神經系統疾病。

醫院仍將是最大的細分市場。

由於醫療保健成本上升和大型企業的存在，預計亞太地區將在預測期內實現最高成長。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球高雪氏症市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球高雪氏症市場趨勢（2018-2023）與預測（2024-2030）
  • 按疾病類型分類的全球高雪氏症市場
    • 1型
    • 2型
    • 3型
    • 其他
  • 按診斷分類的全球高雪氏症市場
    • 體檢
    • 驗血
    • 影像檢查
    • 懷孕前篩檢和產前檢測
    • 其他
  • 按治療分類的全球高雪氏症市場
    • 外科手術
    • 藥品
    • 其他
  • 依最終用途分類的全球高雪氏症市場
    • 醫院
    • 專科診所
    • 居家護理
    • 其他

第4章 2018-2030年市場趨勢及預測分析（依地區）

  • 全球高雪氏症市場（依地區）
  • 北美高雪氏症市場
  • 歐洲高雪氏症市場
  • 亞太高雪氏症市場
  • 其他區域高雪氏症市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球高雪氏症市場成長機會（按疾病類型）
    • 全球高雪氏症市場成長機會（依診斷）
    • 全球高雪氏症市場成長機會（依治療）
    • 全球高雪氏症市場成長機會（依最終用途）
    • 全球高雪氏症市場成長機會（依地區）
  • 全球高雪氏症市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球高雪氏症市場容量擴張
    • 全球高雪氏症市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • ISU Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi SA
  • Takeda Pharmaceutical
簡介目錄

Gaucher Disease Trends and Forecast

The future of the global gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 2.1% from 2024 to 2030. The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

A more than 150-page report is developed to help in your business decisions.

Gaucher Disease by Segment

The study includes a forecast for the global gaucher disease by disease type, diagnosis, treatment, end use, and region.

Gaucher Disease Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Type 1
  • Type 2
  • Type 3
  • Others

Gaucher Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Physical Exam
  • Blood Tests
  • Imaging Tests
  • Preconception Screening and Prenatal Testing
  • Others

Gaucher Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Surgery
  • Medication
  • Others

Gaucher Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Gaucher Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Gaucher Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gaucher disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gaucher disease companies profiled in this report include-

  • Isu Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi S.A.
  • Takeda Pharmaceutical

Gaucher Disease Market Insights

Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Hospitals will remain the largest segment.

APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Features of the Global Gaucher Disease Market

Market Size Estimates: Gaucher disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gaucher disease market by various segments, such as by disease type, diagnosis, treatment, end use and region in terms of($B).

Regional Analysis: Gaucher disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different disease types, diagnosis, treatments, end uses, and region.s for the gaucher disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gaucher disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the gaucher disease market size?

Answer: The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030.

Q.2. What is the growth forecast for gaucher disease market?

Answer: The global gaucher disease market is expected to grow with a CAGR of 2.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the gaucher disease market?

Answer: The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

Q.4. What are the major segments for gaucher disease market?

Answer: The future of the gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key gaucher disease market companies?

Answer: Some of the key gaucher disease companies are as follows:

  • ISU Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi S.A.
  • Takeda Pharmaceutical

Q.6. Which gaucher disease market segment will be the largest in future?

Answer: Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Q.7. In gaucher disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the gaucher disease market by disease type (type 1, type 2, type 3, and others), diagnosis (physical exam, blood tests, imaging tests, preconception screening and prenatal testing, and others), treatment (surgery, medication, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gaucher Disease Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Gaucher Disease Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Gaucher Disease Market by Disease Type
    • 3.3.1: Type 1
    • 3.3.2: Type 2
    • 3.3.3: Type 3
    • 3.3.4: Others
  • 3.4: Global Gaucher Disease Market by Diagnosis
    • 3.4.1: Physical Exam
    • 3.4.2: Blood Tests
    • 3.4.3: Imaging Tests
    • 3.4.4: Preconception Screening and Prenatal Testing
    • 3.4.5: Others
  • 3.5: Global Gaucher Disease Market by Treatment
    • 3.5.1: Surgery
    • 3.5.2: Medication
    • 3.5.3: Others
  • 3.6: Global Gaucher Disease Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Gaucher Disease Market by Region
  • 4.2: North American Gaucher Disease Market
    • 4.2.2: North American Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Gaucher Disease Market
    • 4.3.1: European Gaucher Disease Market by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.3.2: European Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Gaucher Disease Market
    • 4.4.1: APAC Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.4.2: APAC Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Gaucher Disease Market
    • 4.5.1: ROW Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.5.2: ROW Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Gaucher Disease Market by Disease Type
    • 6.1.2: Growth Opportunities for the Global Gaucher Disease Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Gaucher Disease Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Gaucher Disease Market by End Use
    • 6.1.5: Growth Opportunities for the Global Gaucher Disease Market by Region
  • 6.2: Emerging Trends in the Global Gaucher Disease Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Gaucher Disease Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gaucher Disease Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: ISU Abxis
  • 7.2: Johnson & Johnson
  • 7.3: Pfizer
  • 7.4: Protalix Biotherapeutics
  • 7.5: Sanofi S.A.
  • 7.6: Takeda Pharmaceutical